Literature DB >> 22107610

Alternate night nocturnal hemodialysis: the Australian experience.

Peter G Kerr1, John W M Agar, Carmel M Hawley.   

Abstract

Alternate night nocturnal hemodialysis (HD) is a popular modality in Australia. This modality grew out of a desire to increase the availability and accessibility of nocturnal HD without incurring excessive costs. It has proven popular with staff, patients, and administrators. There are limited data to support the benefits of this modality and undoubtedly, more data are required. As in 5-6 times per week nocturnal HD, the major benefits appear to be in phosphate control, volume control, and patient wellbeing. Economically, this approach to nocturnal HD costs much the same as conventional home HD, with only one extra dialysis session every 2 weeks. This review expands on some aspects of this dialysis modality and how it is practiced in Australia.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22107610     DOI: 10.1111/j.1525-139X.2011.00997.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  4 in total

1.  Outcomes after the long interdialytic break: implications for the dialytic prescription.

Authors:  Jennifer E Flythe; Eduardo Lacson
Journal:  Semin Dial       Date:  2012 Jan-Feb       Impact factor: 3.455

Review 2.  How to overcome barriers and establish a successful home HD program.

Authors:  Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

Review 3.  Water quality in conventional and home haemodialysis.

Authors:  Matthew J Damasiewicz; Kevan R Polkinghorne; Peter G Kerr
Journal:  Nat Rev Nephrol       Date:  2012-10-23       Impact factor: 28.314

4.  Daily hemodialysis practices in Australia/New Zealand and in France: a comparative cohort study.

Authors:  Adélaïde Pladys; Sahar Bayat; Cécile Couchoud; Cécile Vigneau; Stephen McDonald
Journal:  BMC Nephrol       Date:  2019-05-07       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.